About: http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_2/w

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_2/w Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Issue
Is Part Of	http://hub.abes.fr/oup/periodical/annonc/2009/volume_20
has manifestation of work	http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_2/m/web http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_2/m/print
Date Copyrighted	2009
Rights	© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org © The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
issue	2
is Is Part Of of	Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial Cancer in adolescents and young adults in north Netherlands (1989-2003): increased incidence, stable survival and high incidence of second primary tumours The emerging epidemic of environmental cancers in developing countries The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma Detection of circulating tumor cells in patients with urothelial cancer Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients Breast cancer in women younger than 25: clinicopathological features and prognostic factors Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000-2006 Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor Vitamin D intake and breast cancer risk: a case-control study in Italy in this issue Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer Sorafenib is active on lung metastases from synovial sarcoma Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients The length of consent documents in oncological trials is doubled in twenty years Treatment of hemodialyzed patient with sunitinib The quest for the ‘bony Grail’ of detecting circulating tumour cells in patients with prostate cancer Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Stopping a trial early in oncology: for patients or for industry?

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata